Cg Oncology [CGON] vs Ionis [IONS] Detailed Stock Comparison
Cg Oncology
NASDAQ
Loading...
Ionis
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Cg Oncology wins in 7 metrics, Ionis wins in 9 metrics, with 0 ties. Ionis appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Cg Oncology | Ionis | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -23.48 | -20.09 | Cg Oncology |
| Price-to-Book Ratio | 3.52 | 15.43 | Cg Oncology |
| Debt-to-Equity Ratio | 0.15 | 314.06 | Cg Oncology |
| PEG Ratio | -0.25 | 0.07 | Cg Oncology |
| EV/EBITDA | -9.71 | -37.04 | Ionis |
| Profit Margin (TTM) | 0.00% | -28.41% | Cg Oncology |
| Operating Margin (TTM) | -28,546.10% | 30.93% | Ionis |
| EBITDA Margin (TTM) | N/A | 30.93% | N/A |
| Return on Equity | -12.00% | -59.91% | Cg Oncology |
| Return on Assets (TTM) | -11.66% | -5.87% | Ionis |
| Free Cash Flow (TTM) | $-78.95M | $-551.29M | Cg Oncology |
| 1-Year Return | -13.09% | 30.58% | Ionis |
| Price-to-Sales Ratio (TTM) | 4,281.49 | 10.34 | Ionis |
| Enterprise Value | $1.53B | $9.45B | Ionis |
| EV/Revenue Ratio | 2,769.44 | 10.01 | Ionis |
| Gross Profit Margin (TTM) | N/A | 99.08% | N/A |
| Revenue per Share (TTM) | $0 | $6 | Ionis |
| Earnings per Share (Diluted) | $-1.78 | $-1.76 | Ionis |
| Beta (Stock Volatility) | N/A | 0.28 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Cg Oncology vs Ionis Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Cg Oncology | 6.88% | 23.30% | 22.75% | 24.18% | 23.26% | 14.15% |
| Ionis | 3.17% | 43.60% | 42.23% | 73.75% | 81.42% | 76.51% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Cg Oncology | -13.09% | -5.60% | -5.60% | -5.60% | -5.60% | -5.60% |
| Ionis | 30.58% | 30.72% | 17.82% | 13.22% | 650.37% | 1,029.70% |
Performance & Financial Health Analysis: Cg Oncology vs Ionis
| Metric | CGON | IONS |
|---|---|---|
| Market Information | ||
| Market Cap | $2.36B | $9.95B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 612,939 | 4,404,577 |
| 90 Day Avg. Volume | 691,970 | 2,912,509 |
| Last Close | $33.07 | $61.23 |
| 52 Week Range | $14.80 - $40.47 | $23.95 - $62.08 |
| % from 52W High | -18.29% | -1.37% |
| All-Time High | $50.23 (Feb 12, 2024) | $86.58 (Apr 08, 2019) |
| % from All-Time High | -34.16% | -29.28% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -1.00% | 1.01% |
| Quarterly Earnings Growth | -1.00% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | -0.28% |
| Operating Margin (TTM) | -285.46% | 0.31% |
| Return on Equity (TTM) | -0.12% | -0.60% |
| Debt to Equity (MRQ) | 0.15 | 314.06 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $8.79 | $3.97 |
| Cash per Share (MRQ) | $8.67 | $14.39 |
| Operating Cash Flow (TTM) | $-93,817,000 | $-230,566,000 |
| Levered Free Cash Flow (TTM) | $396.48M | $-168,629,872 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Cg Oncology vs Ionis
| Metric | CGON | IONS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -23.48 | -20.09 |
| Forward P/E | -17.38 | -16.37 |
| PEG Ratio | -0.25 | 0.07 |
| Price to Sales (TTM) | 4,281.49 | 10.34 |
| Price to Book (MRQ) | 3.52 | 15.43 |
| Market Capitalization | ||
| Market Capitalization | $2.36B | $9.95B |
| Enterprise Value | $1.53B | $9.45B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2,769.44 | 10.01 |
| Enterprise to EBITDA | -9.71 | -37.04 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.28 |
| Book Value per Share (MRQ) | $8.79 | $3.97 |
Financial Statements Comparison: Cg Oncology vs Ionis
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CGON | IONS |
|---|---|---|
| Revenue/Sales | $52,000 | $452.05M |
| Cost of Goods Sold | N/A | $4.15M |
| Gross Profit | N/A | $447.90M |
| Research & Development | $27.47M | $217.46M |
| Operating Income (EBIT) | $-42.20M | $139.84M |
| EBITDA | $-42.18M | $143.86M |
| Pre-Tax Income | $-34.45M | $123.53M |
| Income Tax | N/A | $-20,000 |
| Net Income (Profit) | $-34.45M | $123.55M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CGON | IONS |
|---|---|---|
| Cash & Equivalents | $41.47M | $297.30M |
| Total Current Assets | $701.19M | $2.58B |
| Total Current Liabilities | $22.64M | $897.24M |
| Long-Term Debt | $781,000 | $789.87M |
| Total Shareholders Equity | $704.76M | $631.72M |
| Retained Earnings | $-252.43M | $-2.27B |
| Property, Plant & Equipment | $1.30M | $275.88M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CGON | IONS |
|---|---|---|
| Operating Cash Flow | $-28.85M | $115.11M |
| Capital Expenditures | $-16,000 | $-12.31M |
| Free Cash Flow | $-29.29M | $137.07M |
| Debt Repayment | $0 | $-40,000 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CGON | IONS |
|---|---|---|
| Shares Short | 10.33M | 10.79M |
| Short Ratio | 11.25 | 5.47 |
| Short % of Float | 0.14% | 0.09% |
| Average Daily Volume (10 Day) | 612,939 | 4,404,577 |
| Average Daily Volume (90 Day) | 691,970 | 2,912,509 |
| Shares Outstanding | 76.15M | 157.91M |
| Float Shares | 61.28M | 157.97M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.13% | 1.08% |
Dividend Analysis & Yield Comparison: Cg Oncology vs Ionis
| Metric | CGON | IONS |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |